International staff and one-stop, cutting-edge cellular therapies focused on patient treatment.
Miami, FL (PRWEB) October 02, 2013
Regenestem, a division of the Global Stem Cells Group, Inc., this week announced plans to create a stem cell treatment center in Cancun, Mexico that will offer the most advanced protocols and techniques in cellular medicine to patients from around the world.
The new Regenestem team in Cancun will be led by Rafael Moguel, M.D., a specialist in cardiology and interventional cardiology from Clinic of The Heart facility in Los Cabos, Mexico. An advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions, Moguel is joined by a team of talented and respected physicians from other Latin American countries and the U.S. to provide state-of-the-art patient treatment and follow-up under the Regenestem brand.
Regenestem currently offers stem cell treatments for arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis at various facilities including Far Eastern University in Manila, Philippines, University of Nuevo Leon (University Hospital) in Monterrey, Mexico, and University Maimonides in Buenos Aires, Argentina.
Committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of its international patients, Regenestem provides an international staff and one-stop, cutting-edge cellular therapies focused on patient treatment.
All Regenestem facilities are certified for the medical tourism market, and staff physicians are board-certified or board-eligible and provide services in more than 10 specialties, attracting patients from the United States and around the world.
For more information, visit the Regenestem website, email info(at)regenstem(dot)com, or call 305-224-1858.
Regenestem, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists—professionals trained in the latest cutting-edge techniques in cellular medicine—Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
The Global Stem Cell Foundation was formed as a non-profit charitable organization that aims to fund research on the expanding need for stem cell solutions for patients, and identify best practices between physicians engaged in stem cell treatments in the U.S. and around the world.
To learn more about Global Stem Cells Group, Inc.’s companies, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.